TOP NEWS

Xencor Licenses Antibody Technology To Vir Biotechnology For COVID-19 Treatment

Monrovia, California-based Xencor, a biopharmaceutical company which develops engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, says it is extending a license for its technology to Vir Biotechnology, in use in developing antibodies to treat COVID-19, the disease cased by the novel coronavirus SARS-CoV-2. Financial details of the deal were not announced. Xencor said that Vir will have non-exclusive access to Xencor's Xtend Fc technology to extend the half-life of novel antibodies that Vir is investigating. The two companies already had been working together; the two previously announced a deal in August of 2019, where Xencor licensed its technology for use by Vir in developing and commercializing antibodies as potential treatments for patients with influenza and hepatitis B virus infection.